The U.S. Food and Drug Administration (FDA) recently outlined a path toward reducing and eventually eliminating animal testing—but if your organization hasn’t used the new approach methodologies (NAMs) it references, you may be wondering where to get started.
For nearly 30 years, our modeling and simulation software and expert consultants have supported clients in accelerating their drug development programs while reducing the need for animal studies. We can support your team in identifying opportunities in your monoclonal antibody (mAb) research, implementing NAM strategies, and expanding your in-house skill sets.
